Cardiometabolism clinic

Reducing cardiovascular risk in type 2 diabetes: emerging therapies

John Amerena

Figures

© rasi/stock.adobe.com
© rasi/stock.adobe.com

Abstract

The increased risk of developing atherosclerotic cardiovascular (CV) diseases in people with type 2 diabetes is well recognised, and a focus on reducing CV risk is just as important as glycaemic control. An individualised multifactorial approach to treating patients with type 2 diabetes is recommended, including lifestyle modification and drug therapy to reduce CV risk and improve renal outcomes, blood pressure control, and lipid and glucose levels.

Article Extract

People with type 2 diabetes mellitus are at higher risk of developing atherosclerotic cardiovascular diseases (ASCVDs) than those without diabetes.1,2 Optimal management of type 2 diabetes and associated CV risk factors is recommended to address the increased risk of CV and related diseases.3 Until recently, drug therapy for treating elevated blood glucose levels has had little, if any, impact on reducing ASCVD and its complications in people with type 2 diabetes; however, new glucose-lowering therapies have shown promising results in reducing CV risk. This review will examine the multifactorial approach to reducing CV risk in people with type 2 diabetes, specifically examining the role of the newer glucose-lowering agents that have become available over the past few years.

Figures

© rasi/stock.adobe.com
© rasi/stock.adobe.com